-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
ATR delivered mixed Q1 2026 results with revenue growth of 11% to $983M (+$27M vs. consensus) but flat core sales, while adjusted EPS declined 8% to $1.19 (+$0.04 vs. consensus). EBITDA margins compressed 150 bps to 19.2%, marking the second consecutive quarter of margin decline due to emergency medicine destocking, unfavorable product mix, and operational challenges. The quarter's results underscore growing operational challenges that are now overshadowing ATR's defensive growth characteristics and end-market positioning. Q2 2026 EPS guidance of $1.32-$1.40 suggests sequential improvement and management expects emergency medicine destocking to moderate. ATR announced Gael Touya as next CEO effective September 1, 2026, and returned $131M to shareholders with 1.4x leverage. Two consecutive quarters of margin compression and flat core sales represent notable deterioration from previously consistent profitability improvement.